Vir Biotechnology Inc (VIR) Implied Volatility Current

Tracking VIR implied volatility helps you identify when options premiums on Vir Biotechnology Inc are historically cheap or expensive, and where the best trades are hiding. Vir Biotechnology Inc implied volatility reflects the market's expectation of future price movement: when VIR IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Vir Biotechnology Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For VIR, tracking metrics like VIR IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on VIR signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA.

It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where VIR implied volatility sits today versus where it has been. Our scanner ranks Vir Biotechnology Inc implied volatility against its historical range, surfaces extremes in VIR IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Vir Biotechnology Inc IV is rich or cheap — measure it, then act on it.